NASDAQ Breakout Stocks Alert: SURF, AVAH, BMRA, ENLV, BDSX
The NASDAQ is among the most active and largest stock exchanges in the world. Millions of investors trade billions every day on the exchange, and the stocks that breakout are tracked very closely. This feature would provide you with a comprehensive look into five NASDAQ-listed stocks that have managed to breakout in recent times.
Surface Oncology (NASDAQ:SURF) The clinical-stage immuno-oncology company Surface Oncology is involved in the development of advanced immunotherapies that target the microenvironment of the tumor. On August 2, the company announced its financial results for the second fiscal quarter that ended on June 30, 2023. The company reported cash, cash equivalents, and marketable securities to the tune of $56.3 million at the end of the quarter.
As of December 21, 2022, it had $124.8 million. The net loss for the quarter stood at $28.2 million, which worked out to a $0.46 loss per basic and diluted share. In the prior-year period, the net loss was $25.2 million, which worked out to a $0.46 loss per basic and diluted share. Surface also announced that the proposed merger with Coherus BioSciences, which had been announced on June 16, 2023, would help strengthen Coherus’ pipeline. It would help Coherus get the worldwide rights to two clinical-stage Surface Oncology assets, SRF 388 and SRF 114, which are competitively placed and innovative.
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH): The Atlanta, Georgia-headquartered company boasts locations across 33 states and is known for providing a wide range of pediatric and adult healthcare services. Additionally, Aveanna Healthcare Holdings Inc. also offers case management services, which can help families and patients through the coordination of services between insurers, hospitals, physicians, and other healthcare providers.
The company is going to announce its financial results soon. On July 20, Aveanna announced that it would announce its financial results for the second fiscal quarter before the opening of the markets on August 10, 2023. On the same day, the company would also host a conference call to discuss the financial results at 10 a.m. Eastern Time.
Those who are interested could access the conference call directly through a phone call, and the option would be available for both local and international callers.he replay of the conference call will be made available by the company on August 17. Investors and other interested parties could also visit the investor relations section of the company’s website to listen to the live webcast of the conference call.
Biomerica Inc. (NASDAQ: BMRA) Yesterday, Biomerica Inc. announced that CVS Health had started the rollout of in-store sales of its product, EZ Detect. The product in question is a colorectal disease screening test and would be made available in more than 7,000 stores across the United States through the retail system of CVS Pharmacy.
The company revealed yesterday that it had already shipped the product to distribution centers belonging to CVS Health across the United States. It noted in its news release that it expected the product to hit the shelves at some point next month. More importantly, Biomerica also revealed that it was working with CVS Health with regard to the introduction of another product in the latter’s pharmacies. Colorectal cancer is currently the second-most common cause of cancer-related deaths in the United States. This year, 153,000 people in the United States are projected to be diagnosed with it.
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) The microphage reprogramming clinical-stage immunotherapy firm Enlivex Therapeutics Ltd. made a key announcement on August 2. The company announced that its peer-reviewed clinical and exploratory data from the Phase 1b and Phase IIb clinical trials had been published in Frontiers in Immunology.
The paper was titled “Apoptotic cells for Treatment of acute respiratory distress syndrome (ARDS) Associated with COVID-19”. It had been published in collaboration with researchers at the Hadassah-Hebrew University Medical Center, Barzilai Medical Center, and Ziv Medical Center, all of which are located in Israel. The data presented in the paper had been derived from a total of 21 critical COVID-19 patients who had been treated with Allocetra.
Biodexis Inc. (NASDAQ: BDSX) The data-powered diagnostics solutions firm Biodexis Inc. is focused on lung disease. On July 24, it announced that it would release its financial results for the second fiscal quarter, which ended on June 30, 2023, and on August 7, 2023. The company would also host a conference call on the same day, which would begin at 4–30 p.m. Eastern Time.
The conference call would be made available via webcast as well. On July 12, the company announced that the real-world Oracle study into its product Nodify XL2 had managed to hit the primary endpoint. The data had also been published in PLOS ONE, a noted journal of the Public Library of Science.
